Health
Aptamer Group and Mologic enter commercial partnership to develop aptamer-based SARS-CoV-2 rapid antigen test – News-Medical.net
Aptamer Group, the developer of diagnostic and therapeutic Optimer™ reagents, today announced a commercial partnership with Mologic.

Aptamer Group, the developer of diagnostic and therapeutic Optimer™ reagents, today announced a commercial partnership with Mologic, a leading developer and manufacturer of lateral flow and rapid diagnostic tests.
The partnership will work towards CE marking of Aptamer Group’s AptaDx SARS-CoV-2 lateral flow rapid antigen test for professional use, to detect the SARS-CoV-2 spike protein antigen in anterior nasal swabs. Initial test analysis with laboratory samples has demonstrated excellent sensitivity…
-
General23 hours ago
Wondering about winter | The Spectator Australia
-
Noosa News20 hours ago
This 42-Kilometre Walking Trail on the NSW North Coast Weaves Through Ancient Rainforest, Volcanic Mountains and Spectacular Waterfalls
-
Noosa News22 hours ago
Jane Bunn weather: Cyclone Errol forms as effects of Alfred still felt across Queensland
-
General22 hours ago
Parents of Heidi, 3, remember ‘beautiful’ daughter killed in Ocean Grove crash